In last trading session, Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) saw 0.54 million shares changing hands with its beta currently measuring 0.33. Company’s recent per share price level of $0.22 trading at -$0.03 or -12.57% at ring of the bell on the day assigns it a market valuation of $17.74M. That closing price of BCLI’s stock is at a discount of -259.09% from its 52-week high price of $0.79 and is indicating a premium of 40.91% from its 52-week low price of $0.13. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.32 million shares which gives us an average trading volume of 432.36K if we extend that period to 3-months.
For Brainstorm Cell Therapeutics, Inc. (BCLI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.03 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) trade information
Upright in the red during last session for losing -12.57%, in the last five days BCLI remained trading in the red while hitting it’s week-highest on Tuesday, 09/24/24 when the stock touched $0.22 price level, adding 16.6% to its value on the day. Brainstorm Cell Therapeutics, Inc.’s shares saw a change of -18.50% in year-to-date performance and have moved -8.36% in past 5-day. Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) showed a performance of -30.47% in past 30-days. Number of shares sold short was 1.4 million shares which calculate 3.56 days to cover the short interests.
Brainstorm Cell Therapeutics, Inc. (BCLI) estimates and forecasts
Statistics highlight that Brainstorm Cell Therapeutics, Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -60.60% of value to its shares in past 6 months, showing an annual growth rate of 62.75% while that of industry is 17.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 10.57% during past 5 years.
Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s Major holders
Insiders are in possession of 8.99% of company’s total shares while institution are holding 15.42 percent of that, with stock having share float percentage of 16.94%. Investors also watch the number of corporate investors in a company very closely, which is 15.42% institutions for Brainstorm Cell Therapeutics, Inc. that are currently holding shares of the company. ARMISTICE CAPITAL, LLC is the top institutional holder at BCLI for having 7.92 million shares of worth $2.68 million. And as of 2024-06-30, it was holding 12.2302 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 1.51 million shares on 2024-06-30. The number of shares represents firm’s hold over 2.3334 of outstanding shares, having a total worth of $0.51 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 30, 2024 , the former fund manager was holding 1.06 shares of worth $0.24 million or 1.33% of the total outstanding shares. The later fund manager was in possession of 401.01 shares on Jun 30, 2024 , making its stake of worth around $89225.0 in the company or a holder of 0.50% of company’s stock.
